We're excited to see new medical therapy options 💊 for hypertrophic cardiomyopathy with class 1 recommendations in the newly released 2024 guidelines for management. https://ow.ly/4L7050RGmT4 #Cardiology
egnite Health’s Post
More Relevant Posts
-
"Global Talent Research Strategist | Market Intelligence Specialist | Uncovering insights to drive business growth and optimize talent acquisition strategies"
Philips ultra-low contrast PCI for CAD patients at high risk for AKI Did you know that 1 in 3 CAD patients are at high-risk for acute kidney injury? Learn how procedural excellence enables reduced contrast during PCI. https://lnkd.in/dU-zPgF7 #Beyond1000 #IGT #Cardiology
To view or add a comment, sign in
-
-
Many heart failure with reduced ejection fraction (HFrEF) patients are not prescribed any guideline-directed medical therapy. Interested in more HFrEF insights, like which GDMT classes are being prescribed less often? Download our report: https://ow.ly/xggB50PtfsC #DigitalHealth #Cardiology
To view or add a comment, sign in
-
-
What is apical hypertrophic cardiomyopathy (HCM), and how is it different from other morphological variants? The apical HCM morphological variant is poorly understood, and presents with different challenges and risks than the more common variants. Gain an overview of the clinical features of apical HCM, how it can be identified, and associated risks by attending our free CME webinar. Join leading experts Steve Ommen and Gaby Captur on Sep 25th to learn more. Register now! https://bit.ly/3qbYBfV #CardioEd #MedicalEducation #Cardiology
To view or add a comment, sign in
-
-
MD #PrecisionMedicine 精密医学 thought & technology leader, Keynote Speaker, industry advisor 30K+ Followers #Biotech #Diagnostics #DrugDiscovery #Innovation #StartUps #ArticialIntelligence #Investing
Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients @ScienceMag https://buff.ly/44NNUPB #Cardiology #PrecisionMedicine #DrugDiscovery #DrugDevelopment #Innovation #Biomarkers #TranslationalResearch #TranslationalMedicine
To view or add a comment, sign in
-
-
Missed our groundbreaking webinar on Transcatheter Mitral Valve Replacement vs. Medical Therapy in Managing Secondary Mitral Valve Regurgitation? Don't worry, you can catch up now on YouTube! Watch the session led by Dr. Shrouq Ramadan and stay updated on the latest in heart care innovations. Click the link to watch now: https://lnkd.in/d5Vq3QMa #TranscatheterValveBreakthroughs #Cardiology #HeartCare #mitralvalve #cardiology #interventionalcardiology #webinarseries
To view or add a comment, sign in
-
-
⏰ 1 hour until we go live! There's still time to register and engage with our experts—ask your Questions live and be part of the discussion! Can't make it live? No worries, you can access the on-demand session later. https://ow.ly/3pga50Qvw8I #Cardiology #MedicalWebinar #MedicalEducation #PatientOutcomes #PatientPerspectives #Cardiologist
To view or add a comment, sign in
-
-
In pts w/ worsening HFREF, upfront low-dose quintuple Rx: Consider vericiguat add-on to the 4 pillars and for those w/iron deficiency, IV iron. Rapid uptitration to target doses in 4 - 6 weeks. What about add-on to IV furosemide in AHF? SGLT2i or acetazolamide? Worth reading this framework for patients classified as having worsening heart failure (w/reduced EF). Reference embedded on main illustration #heartfailure #cardiology
To view or add a comment, sign in
-
-
New #ESCTVToday episode 🤗 Michael Boehm discusses the use of beta-blockers in patients after myocardial infarction. What are the key findings of the REDUCE-AMI trial and the most important implications for current clinical practice? https://bit.ly/4aAav4n #CVD #MI #cardiology
#ESCTVToday
To view or add a comment, sign in
Experienced PharmD and Clinical Research Associate Working to Drive Value and Innovation in Healthcare and Life Sciences
2moI enjoyed reading about the new addition of myosin inhibitors in patients with obstructive hypertrophic cardiomyopathy (HCM) who do not derive adequate symptom relief from 1st line drug therapy. Thank you for sharing this publication!